Monopar Therapeutics Inc - ESG Rating & Company Profile powered by AI
The ESG score for Monopar Therapeutics Inc represents the company's transparency towards the UN SDGs. This analysis of Monopar Therapeutics Inc uses information from across the internet as well as from public filings by Monopar Therapeutics Inc. This page displays a free E,S&G assessment for Monopar Therapeutics Inc.
Monopar Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 8.0, social score of 3.2 and governance score of 6.0.
5.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
541 | Wntresearch AB | 5.8 | High |
541 | Zenotech Laboratories Ltd | 5.8 | High |
579 | Monopar Therapeutics Inc | 5.7 | High |
579 | Caplin Point Laboratories Ltd | 5.7 | High |
579 | Biotest AG | 5.7 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Monopar Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Monopar Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Monopar Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Monopar Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Monopar Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Monopar Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Monopar Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Monopar Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Monopar Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Monopar Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Monopar Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Monopar Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Monopar Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Monopar Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Monopar Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Monopar Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Monopar Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Monopar Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.